BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/12/2021 11:22:25 AM | Browse: 280 | Download: 292
 |
Received |
|
2021-03-12 00:09 |
|
Peer-Review Started |
|
2021-03-12 00:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-03 05:10 |
|
Revised |
|
2021-05-11 20:51 |
|
Second Decision |
|
2021-08-24 03:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-08-25 08:05 |
|
Articles in Press |
|
2021-08-25 08:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-09-20 01:18 |
|
Typeset the Manuscript |
|
2021-11-09 09:41 |
|
Publish the Manuscript Online |
|
2021-11-12 11:22 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: Systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Faiza Ahmed, Jennifer Onwumeh-Okwundu, Zeynep Yukselen, Maria-Kassandra Endaya Coronel, Madiha Zaidi, Prathima Guntipalli, Vamsi Garimella, Sravya Gudapati, Marc Darlene Mezidor, Kim Andrews, Mohamad Mouchli and Endrit Shahini |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Endrit Shahini, MD, MSc, Research Scientist, Department of Gastroenterology and Digestive Endoscopy Unit, National Institute of Research "Saverio De Bellis", Via Turi 27, Castellana Grotte (Bari) 70013, Italy. endrit.shahini@irccsdebellis.it |
| Key Words |
Hepatic malignancy; Combination systemic therapy; Immunogenetic therapy; Liver transplantation; Barcelona clinic liver cancer; Transarterial chemoembolization |
| Core Tip |
Hepatocellular carcinoma (HCC), the most common primary malignancy of the liver is a major reason for cancer-related deaths. Combination immunogenic therapy for the treatment of advanced HCC is attracting increasing attention because of the superiority of clinical results compared to sorafenib, the standard of care. The combination therapy of atezolizumab-bevacizumab has been compared against monotherapies sorafenib, and atezolizumab. The current findings indicate that the combination therapy has first-line therapeutic effectiveness in improving survival rates in patients with unresectable HCC and non-decompensated liver disease. |
| Publish Date |
2021-11-12 11:22 |
| Citation |
Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i11/1813.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i11.1813 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
